The Library
Empagliflozin improves primary haemodynamic parameters and attenuates the development of atherosclerosis in high fat diet fed APOE knockout mice
Tools
Dimitriadis, Georgios K., Nasiri-Ansari, Narjes, Agrogiannis, Georgios, Kostakis, Ioannis D., Randeva, Manpal S., Nikiteas, Nikolaos, Patel, Vanlata H., Kaltsas, Gregory, Papavassiliou, Athanasios G., Randeva, Harpal S. and Kassi, Eva (2019) Empagliflozin improves primary haemodynamic parameters and attenuates the development of atherosclerosis in high fat diet fed APOE knockout mice. Molecular and Cellular Endocrinology, 494 . 110487. doi:10.1016/j.mce.2019.110487 ISSN 0303-7207.
|
PDF
WRAP-empagliflozin-improves-primary-haemodynamic-parameters-attenuates-development-atherosclerosis-high-fat-diet-fed-APOE-knockout-mice-Randeva-2019.pdf - Accepted Version - Requires a PDF viewer. Available under License Creative Commons Attribution Non-commercial No Derivatives 4.0. Download (2810Kb) | Preview |
Official URL: http://dx.doi.org/10.1016/j.mce.2019.110487
Abstract
The effects of long-term treatment with empagliflozin on biochemical and immunohistochemical markers related to atherosclerosis and atherosclerosis development in the aorta of apolipoprotein E knockout [Apo-E (−/−)] mice were evaluated in this study. Empagliflozin-treated mice had lower total cholesterol (P < 0.05), fasting glucose (P < 0.01), heart rate (P < 0.01) and diastolic blood pressure (DBP) (P < 0.05) compared to controls. Histomorphometry revealed reduced atherosclerotic lesion progress approaching statistical significance (P = 0.06) and approximately 50% wider lumen area for the Empagliflozin treated mice group. Although empagliflozin significantly reduced Vcam-1 and Mcp-1 (P < 0.05, P < 0.01, respectively) and marginally induced Timp-1 and Timp-2 mRNA expression (P < 0.08, P = 0.1 respectively), immunohistochemistry revealed a marginal reduction in VCAM-1 and MMP-9 (P = 0.1) without affecting the expression of TIMP-2 and MCP-1 in atherosclerotic lesions.
Item Type: | Journal Article | ||||||||
---|---|---|---|---|---|---|---|---|---|
Subjects: | R Medicine > RC Internal medicine R Medicine > RM Therapeutics. Pharmacology |
||||||||
Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Biomedical Sciences Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||||||
Library of Congress Subject Headings (LCSH): | Atherosclerosis -- Treatment, Drugs -- Testing , Diabetes -- Oral therapy | ||||||||
Journal or Publication Title: | Molecular and Cellular Endocrinology | ||||||||
Publisher: | Elsevier | ||||||||
ISSN: | 0303-7207 | ||||||||
Official Date: | 20 August 2019 | ||||||||
Dates: |
|
||||||||
Volume: | 494 | ||||||||
Article Number: | 110487 | ||||||||
DOI: | 10.1016/j.mce.2019.110487 | ||||||||
Status: | Peer Reviewed | ||||||||
Publication Status: | Published | ||||||||
Access rights to Published version: | Restricted or Subscription Access | ||||||||
Date of first compliant deposit: | 27 November 2019 | ||||||||
Date of first compliant Open Access: | 10 June 2020 | ||||||||
Related URLs: |
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |
Downloads
Downloads per month over past year